TTA in Treatment of Diabetes and Dyslipidemia

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of the study is to evaluate the short-term effects of tetradecylthioacetic acid (TTA) on plasma lipids and glucose in male patients with type 2 diabetes mellitus and dyslipidemia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Haukeland University Hospital
• Collaborator: University of Bergen
• Treatments: 1-(carboxymethylthio)tetradecane

Criteria

Inclusion Criteria:

• type 2 diabetes mellitus with HbA1c 8.0-12.0%,

• fasting S-triacylglycerol 2.0-10.0 mmol/L,

• body mass index 25-40 kg/m2 and/or waist/hip ratio > 0.90.

Exclusion Criteria:

• fasting total cholesterol >10 mmol/L,

• blood pressure 170/110 mmHg

• other significant disease

• Use of any corticosteroid, anticoagulant or lipid-lowering drug 2 weeks prior to inclusion.